Literature DB >> 17993249

Progressive dysregulation of autonomic and HPA axis functions in HIV-1 clade C infection in South India.

Seetharamaiah Chittiprol1, Adarsh M Kumar, P Satishchandra, K Taranath Shetty, R S Bhimasena Rao, D K Subbakrishna, Mariyamma Philip, K S Satish, H Ravi Kumar, Mahendra Kumar.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection causes a wide spectrum of abnormalities in neurological, neuropsychological, and neuroendocrinological functions. Several studies report disturbance in autonomic nervous system (ANS) and hypothalamic pituitary-adrenal (HPA) axis function in HIV-1B infected individuals. However, no such investigations on the effect of HIV-1 clade C infection, particularly during the initial phase of the disease progression, have been reported. The present investigations were carried out longitudinally over a 2-year period at 12 monthly intervals in clinically asymptomatic HIV-1 clade C seropositive patients (n=120) and seronegative control subjects (n=29). We determined both the basal levels and the dynamic changes in plasma levels of norepinephrine (NE), epinephrine (E), adrenocorticotrophic hormone (ACTH) and cortisol (CORT). Studies were also extended longitudinally (at three separate yearly visits of each participant), to evaluate the response of autonomic and HPA axis to mirror star tracing challenge test (MSTCT) and the values were determined as area under the curve (AUC, corrected for baseline levels of NE, E, ACTH, and CORT). The findings show that the values of basal plasma NE levels, as well as NE response to MSTCT (AUC) at the first visit of HIV-1 seropositive individuals did not differ from those found in the control subjects (NE, pg/ml, HIV-1C=313.5+/-12.7 vs. controls=353.0+/-21.3; p=NS; AUC, HIV-1C=225+/-14.75 vs. controls=232.7+/-19.34; p=NS, respectively). At the subsequent two visits of HIV-1 positive patients however, NE response to MSTCT challenge was progressively attenuated (AUC=235+/-19.5 and 162.7+/-13.6; p<0.01 and 0.05, respectively) compared to that found at the first visit. On the other hand, plasma levels of E as well as E response to MSTCT at the first visit were significantly lower in HIV-1C seropositive individuals compared to those in the control subjects (pg/ml, HIV-1C=77.30+/-5.7 vs. controls=119.1+10.5; p<0.05; AUC, HIV-1C =83.29+/-7.5 vs. controls=172.3+/-18.9; p<0.001), but no further change was observed in AUC of E in response to MSTCT at the two subsequent yearly visits. The basal plasma levels of ACTH in HIV-1C seropositives were not different than in the control subjects (pg/ml: HIV-1C=20.0+/-0.9 vs. controls=23.1+/-1.6; p=NS), but ACTH response to MSTCT in HIV-1C seropositive patients at the first visit was lower than in the controls (AUC, HIV-1C=23.57+/-1.5 vs. controls=30.94+/-3.5; p<0.05), and fluctuated between high and low at the second and third visits (AUC, 28.89+/-2.3 and 21.69+/-2.36, respectively). However, the baseline plasma levels of cortisol as well as the response of cortisol to MSTCT (AUC) in HIV-1C seropositive individuals were higher than in the control subjects at the first visit (mug/dl, HIV-1C=9.83+/-0.39 vs. controls=6.3+/-0.56; p<0.05; AUC, HIV-1C=12.31+/-0.7 vs. control=9.18+/-0.9; p<0.05), and remained high at the two subsequent yearly follow up visits of HIV-1C (AUC, 11.8+/-0.86 and 11.98+/-0.77, respectively). These findings demonstrate attenuated autonomic functions, a disconnection between response of ACTH and cortisol to the MSTCT challenge, and an inverse relationship between plasma levels of catecholamine(s) and cortisol. Since plasma catecholamines and cortisol are the peripheral mediators of the autonomic and HPA axis function, the findings of this study reflect the overall adverse effect of HIV-1C infection on autonomic as well as HPA axis functions. The findings, apart from being the first to demonstrate the progressive dysregulation of autonomic nervous system and HPA axis function among HIV-1C infected seropositive individuals much ahead of the onset of acquired immunodeficiency syndrome (AIDS), also suggest that MSTCT, involving visuoconstructive cognitive abilities, is an effective stressor for unraveling the underlying dysfunctions in the neuroendocrine functions in health and disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17993249     DOI: 10.1016/j.psyneuen.2007.09.006

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  12 in total

1.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

Review 2.  Childhood maltreatment and HIV-associated neurocognitive disorders share similar pathophysiology: a potential sensitisation mechanism?

Authors:  Jacqueline S Womersley; Soraya Seedat; Sian M J Hemmings
Journal:  Metab Brain Dis       Date:  2017-07-05       Impact factor: 3.584

Review 3.  Current understanding of HIV-associated neurocognitive disorders pathogenesis.

Authors:  Patrick Gannon; Muhammad Z Khan; Dennis L Kolson
Journal:  Curr Opin Neurol       Date:  2011-06       Impact factor: 5.710

Review 4.  Neuromuscular diseases associated with HIV-1 infection.

Authors:  Jessica Robinson-Papp; David M Simpson
Journal:  Muscle Nerve       Date:  2009-12       Impact factor: 3.217

5.  Sympathetic nervous system contributes to enhanced corticosterone levels following chronic stress.

Authors:  Steven A Lowrance; Amy Ionadi; Erin McKay; Xavier Douglas; John D Johnson
Journal:  Psychoneuroendocrinology       Date:  2016-02-26       Impact factor: 4.905

6.  HIV-1 clade C infection and progressive disruption in the relationship between cortisol, DHEAS and CD4 cell numbers: a two-year follow-up study.

Authors:  Seetharamaiah Chittiprol; Adarsh M Kumar; K Taranath Shetty; H Ravi Kumar; P Satishchandra; R S Bhimasena Rao; V Ravi; A Desai; D K Subbakrishna; Mariamma Philip; K S Satish; Mahendra Kumar
Journal:  Clin Chim Acta       Date:  2009-07-01       Impact factor: 3.786

7.  5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.

Authors:  Jason J Paris; ShiPing Zou; Yun K Hahn; Pamela E Knapp; Kurt F Hauser
Journal:  Brain Behav Immun       Date:  2016-01-13       Impact factor: 7.217

8.  HIV and mental health: An overview of research from India.

Authors:  Nishanth Jayarajan; Prabha S Chandra
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

9.  Stress biomarkers as outcomes for HIV+ prevention: participation, feasibility and findings among HIV+ Latina and African American mothers.

Authors:  Dorie A Glover; Elena F Garcia-Aracena; Patricia Lester; Eric Rice; Mary Jane Rothram-Borus
Journal:  AIDS Behav       Date:  2009-04-07

10.  Chronic distress and the vulnerable host: a new target for HIV treatment and prevention?

Authors:  Carlo Contoreggi; George P Chrousos; Michele Di Mascio
Journal:  Neurobehav HIV Med       Date:  2016-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.